ArticleIntensive care medicine experimental2026
Proteomic signatures of renal recovery from acute kidney injury-a translational study in critically ill postoperative patients.
Article in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) is a common complication in critically ill patients and frequently progresses to persistent renal dysfunction. However, mechanisms underlying renal recovery versus persistent dysfunction remain poorly understood. Plasma proteomic profiling may identify proteins and biological pathways associated with the development of acute kidney disease (AKD) subsequent to AKI. MATERIAL AND
methodsWe conducted a plasma proteomics study within a prospective, single-centre observational cohort of 205 critically ill adult patients in Germany with moderate AKI (KDIGO stage 2) and predefined risk factors for AKI progression (mechanical ventilation and/or vasopressor therapy). Plasma samples from 195 patients were available for analysis in sufficient quantity. The primary outcome was AKD, defined as persistent AKI (KDIGO stage 2 or 3) or death seven days after AKI diagnosis. High-resolution mass spectrometry quantified protein abundances in non-depleted and immunodepleted plasma samples. Proteins associated with AKD were assigned using biostatistical analyses and selected candidates were validated by enzyme-linked immunosorbent assay (ELISA) in the entire cohort.
resultsOut of 195 patients, 103 developed AKD (52.8%). Proteomic profiling assigned 29 proteins in undepleted plasma and 38 proteins in depleted plasma that were significantly associated with development of AKD. In undepleted plasma, gelsolin and Zinc-alpha-2-glycoprotein were prominent candidates. In depleted plasma, S100A9, a component of the Calprotectin complex, showed the strongest association with AKD development. ELISA validation demonstrated higher plasma concentrations of Calprotectin (S100A8/A9) in patients who progressed from AKI to AKD.
conclusionsUnbiased plasma proteomics revealed several proteins associated with development of AKD following moderate AKI in critically ill patients. Elevated Calprotectin (S100A8/A9) levels were independently associated with AKD development in ELISA analyses, suggesting a potential role in AKI chronification. Further studies are warranted to validate these findings and explore their mechanistic and clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.